Beneficial and ominous aspects of the pleiotropic action of erythropoietin

作者: Wolfgang Jelkmann , Klaus Wagner

DOI: 10.1007/S00277-004-0911-6

关键词:

摘要: The primary function of the glycoprotein hormone erythropoietin (Epo) is to promote red cell production by inhibiting apoptosis erythrocytic progenitors in hemopoietic tissues. However, functional Epo receptors (Epo-R) have recently been demonstrated various nonhemopoietic tissues indicating that a more pleiotropic viability and growth factor. Herein, vitro vivo effects brain cardiovascular system are reviewed. In addition, therapeutic impact oncology considered, including question whether might tumor growth. Convincing evidence available acts as neurotrophic neuroprotective factor brain. prevents neuronal cells from hypoxia-induced glutamate-induced death. Epo-R expressed neurons glia specific regions supports survival ischemic potential has already confirmed clinical trial on patients with acute stroke. With respect vasculature, both endothelial smooth muscle cells. promotes angiogenesis stimulates endothelin other vasoactive mediators. cardiomyocytes. role myocardial protectant at focus present research. therapy practiced primarily maintain hemoglobin concentration above transfusion trigger reduce fatigue. increased oxygenation may improve efficacy chemotherapy radiotherapy. often express Epo-R. Therefore, careful studies required fully exclude recombinant human (rHuEpo)

参考文章(216)
Todd Gregory, Channing Yu, Averil Ma, Stuart H. Orkin, Gerd A. Blobel, Mitchell J. Weiss, GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. Blood. ,vol. 94, pp. 87- 96 ,(1999) , 10.1182/BLOOD.V94.1.87.413K41_87_96
Anna-Leena Sirén, Friederike Knerlich, Wolfgang Poser, Christoph H. Gleiter, Wolfgang Brück, Hannelore Ehrenreich, Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain Acta Neuropathologica. ,vol. 101, pp. 271- 276 ,(2001) , 10.1007/S004010000297
W. Jelkmann, Effects of Erythropoietin on Brain Function Current Pharmaceutical Biotechnology. ,vol. 6, pp. 65- 79 ,(2005) , 10.2174/1389201053167257
Beverly A. Teicher, Physiologic Mechanisms of Therapeutic Resistance: Blood Flow and Hypoxia Hematology-oncology Clinics of North America. ,vol. 9, pp. 475- 506 ,(1995) , 10.1016/S0889-8588(18)30105-9
Ryuzo Sasaki, Seiji Masuda, Masaya Nagao, Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production. International Journal of Hematology. ,vol. 70, pp. 1- 6 ,(1999)
Domenico Ribatti, Marco Presta, Angelo Vacca, Roberto Ria, Roberta Giuliani, Patrizia Dell’Era, Beatrice Nico, Luisa Roncali, Franco Dammacco, Human Erythropoietin Induces a Pro-Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo Blood. ,vol. 93, pp. 2627- 2636 ,(1999) , 10.1182/BLOOD.V93.8.2627
Mario Cazzola, Francesco Mercuriali, Carlo Brugnara, Use of recombinant human erythropoietin outside the setting of uremia Blood. ,vol. 89, pp. 4248- 4267 ,(1997) , 10.1182/BLOOD.V89.12.4248
S T Sawyer, The two proteins of the erythropoietin receptor are structurally similar Journal of Biological Chemistry. ,vol. 264, pp. 13343- 13347 ,(1989) , 10.1016/S0021-9258(18)51634-3